Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA's potential effects on addiction treatment.
PharmAla Signs Sale Agreement With Numinus
PharmAla Biotech Holdings, a biotech company researching, developing and manufacturing proprietary MDMA "LaNeo" and new MDMA derivatives (aka MDXX-class molecules) entered into a binding sales agreement with Numinus Wellness to provide its GMP MDMA LaNeo for a prospective clinical trial, now holding for approval.
PharmAla's...
Login or create a forever free account to read this news
Sign up/Log in